Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of Cervarix efficacy in young women
NCT00120848Phase 2Completed
- Sponsor
- GSK
- Start
- Nov 2003
- Primary completion
- Jul 2007
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 3
01
Overview
Phase 2, single-blind trial of Human papillomavirus type 16 L1 capsid protein residues 2-471 antigen in human papillomavirus infection (2 arms), sponsored by GSK. Primary endpoint: Incident cervical infection with HPV-16 and/or HPV-18. Started Nov 2003; status: completed.
02
Drugs
Human papillomavirus type 16 L1 capsid protein residues 2-471 antigen
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT00120848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00120848.